logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Pharma's TH-302 Receives EC's Orphan Drug Designation

Threshold Pharmaceuticals, Inc. (THLD) Friday said the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.

Soft tissue sarcoma is an aggressive form of cancer and there is a significant unmet medical need for the condition. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed not effectively treated with current therapy.

Threshold is currently conducting a pivotal Phase 3 study in soft tissue sarcoma, comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," said Barry Selick, Ph.D., CEO of Threshold.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Casino operator Las Vegas Sands Corp. (LVS), Wednesday reported an increase in profit for the first quarter, gambling business in Macao, China, the world's biggest gambling market, revives. Earnings for the quarter trumped Wall Street expectations, as did revenues. First-quarter profit rose to $480... Photo and video sharing app Instagram has touched a new milestone with an impressive 700 million users. The Museum of Failures is set to open in Helsingborg, Sweden in June. The museum will feature a collection of innovation failures that will provide visitors a fascinating learning experience. The museum's collection consists of over sixty epic failed products and services from around the world.
comments powered by Disqus
Follow RTT